Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin antigen of Influenza A virus H1N1 subtype (HA (sometimes "HA H1N1" in subtype context))
- Target
- HA (sometimes "HA H1N1" in subtype context)
- Molecular classification
- Viral glycoprotein, Class I fusion protein, Antigen
01
Overview
The Hemagglutinin antigen of Influenza A virus H1N1 subtype is a homotrimeric glycoprotein on the viral surface, composed of subunits HA1 and HA2 derived from cleavage of the precursor HA0. Its globular head domain binds sialic acid receptors on host cells, initiating infection, while the stem domain mediates fusion of viral and host membranes in acidic endosomes[1][3][5][2]. Hemagglutinin is the principal antigen for influenza immunity: neutralizing antibodies (often elicited by vaccination) bind to regions on HA, blocking viral attachment or fusion. Its frequent antigenic shifts and drifts cause seasonal flu outbreaks and occasional pandemics. HA's structure and function make it a prime target for therapeutic antibodies and ongoing universal vaccine research[1][5][3][4][2].
- Other names
- Influenza H1N1 hemagglutininHA protein (H1N1)H1 hemagglutininInfluenza A virus hemagglutininH1 subtype hemagglutinin
02
Mechanism of action
Neutralizing antibodies block receptor binding or fusion activity of HA. Vaccines elicit immune responses against HA, preventing viral entry.
03
Biological functions
Attachment to host cell receptors (sialic acid binding)Membrane fusion (facilitating entry of the viral genome into the host cell)Major target of neutralizing antibodiesRed blood cell agglutination (used in laboratory diagnostics)
04
Disease associations
Infection (primary driver of Influenza A pathogenesis)Pandemic and seasonal flu outbreaks (notably in the 1918 and 2009 pandemics)
05
Safety considerations
Antigenic drift and shift (HA undergoes frequent mutations, leading to vaccine escape and requiring regular vaccine updates)Hypervariability in the head domain (may reduce vaccine and antibody effectiveness)Potential hypersensitivity reactions to HA in vaccines
06
Interacting drugs
Antibody therapies (monoclonal antibodies targeting HA, e.g., anti-HA Fab fragments like C05)
1 more in the full profile.
07
Biomarkers
Hemagglutination inhibition assay (used to quantify neutralizing antibodies and vaccine efficacy)Antibody titers against HA (used in patient selection for immunotherapy and vaccine studies)
Beyond the preview
Go deeper on Hemagglutinin antigen of Influenza A virus H1N1 subtype (HA (sometimes "HA H1N1" in subtype context)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemagglutinin antigen of Influenza A virus H1N1 subtype (HA (sometimes "HA H1N1" in subtype context)).